FDA delivered on a promise for quick review of new products that “address critical national health priorities” this week. The agency granted approval for Wegovy HD – a 7.2 mg high-dose regimen for semaglutide in obesity. The “priority” rationale can be whatever you like, depending on your perspective. So Much Winning For Novo Nordisk, it’s […]
